FDA accepts EffRx NDA for EX101 to treat osteoporosis

NewsGuard 100/100 Score
May 12 2011

EffRx Pharmaceuticals SA, an Epalinges/Lausanne, Switzerland based drug delivery company announces that the New Drug Application (NDA) for the company's lead development program EX101 has been accepted for filing by the US Food and Drug Administration.

EX101 is a proprietary buffered effervescent dosage form of alendronate sodium administered once weekly for treatment of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. The EX101 formulation is the first and only effervescent bisphosphonate alternative to tablets. EX101 has a pleasant taste of strawberry and is quickly and completely dissolved.

EffRx is in the process of securing partnership for distribution of EX101 in the USA and Japan. In the rest of the world EffRx has licensed commercialization of EX101 to Nycomed.

Source: EffRx Pharmaceuticals

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , ,

Comments (0)

Suggested Reading

Living near green spaces linked to stronger bones in young children
Osteoporosis model rats show improved healing with FGF-2 treatment
New study reveals optimal drug sequencing for postmenopausal osteoporosis treatment
Higher doses of topical corticosteroids linked to increased risks of osteoporosis and bone fractures
Prevention of post-menopausal osteoporosis in rats by sesame oil
Sesame oil supplementation: a potential breakthrough in postmenopausal osteoporosis prevention?
Living near green spaces linked to higher bone density and lower osteoporosis risk
Tea consumption increases bone density and reduces the risk of osteoporosis

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Female ginseng compound holds promise as osteoporosis treatment